StockWatch
·
Pharmaceuticals
Board Meeting6 Aug 2026, 03:38 pm

Albert David Q1 FY27: standalone PAT surges 303% YoY to ₹32 Cr as margins expand sharply

AI Summary

Albert David Limited's standalone Q1 FY27 (quarter ended June 30, 2026) results show revenue from operations up 43.6% YoY to ₹101.34 Cr (₹70.57 Cr in Q1 FY26), and net profit up 303% YoY to ₹32.00 Cr (₹7.94 Cr in Q1 FY26) — a sharp jump in profitability. Net profit margin expanded to 24.75% from 8.57% a year ago. Sequentially the company swung from a ₹21.43 Cr net loss in Q4 FY26 to this quarter's ₹32.00 Cr profit, but Q4 figures are the balancing residual between audited full-year numbers and the nine-month run-rate (per the filing's own note), so that QoQ swing is less informative than the YoY trend, which is the primary read here. The margin expansion was driven almost entirely by expense discipline against a strong topline: total expenses rose just 11.1% YoY (₹93.50 Cr vs ₹84.16 Cr) even as revenue grew 43.6%, with employee benefit costs actually declining YoY (₹25.55 Cr vs ₹28.43 Cr). Reported PAT was also lifted by a ₹2.35 Cr prior-year tax credit booked this quarter; excluding it, adjusted PAT growth is still a strong ~274% YoY (₹29.65 Cr adjusted vs ₹7.94 Cr), confirming the growth is largely operational rather than a tax-line artefact. Pre-tax profit (before exceptional items, of which there were none) came in at ₹35.79 Cr against ₹8.44 Cr a year ago. Albert David carries no visible analyst/street coverage — a web search for Q1 FY27 previews or consensus estimates on the company returned no results, consistent with its small-cap, standalone-only profile. There is also no prior management guidance on record and none surfaced in search, so vsGuidance is unknown rather than a miss. The result comes alongside a leadership transition: Amit Mahla, appointed Whole-time Director & CEO on June 19, 2026, signs this filing, following a cluster-head resignation on July 4, 2026 — the new CEO's first quarterly print shows a clear margin improvement, though one quarter is too early to attribute it to the leadership change. Basic EPS (not annualised) was ₹56.07 versus ₹13.91 a year ago and -₹37.56 in Q4 FY26. With no exceptional items and the tax-credit effect isolated, the quarter sets up a watch on whether the ~43.6% revenue growth pace and the lower employee-cost run-rate hold into Q2 FY27, and whether the effective tax rate normalizes toward the ~17% implied by this quarter's core (non-credit) tax expense.

Key Highlights

  • Revenue from operations up 43.6% YoY to ₹101.34 Cr (₹70.57 Cr in Q1 FY26); net profit up 303% YoY to ₹32.00 Cr (₹7.94 Cr in Q1 FY26), ~274% adjusted for a one-off tax credit
  • Net profit margin expanded to 24.75% from 8.57% YoY, as total expenses rose only 11.1% YoY (₹93.50 Cr vs ₹84.16 Cr) against 43.6% revenue growth
  • Sequential swing from a ₹21.43 Cr net loss in Q4 FY26 to ₹32.00 Cr profit this quarter — QoQ comparison is less meaningful since Q4 is a full-year balancing figure
  • Employee benefit expenses declined YoY to ₹25.55 Cr from ₹28.43 Cr, a key driver of the margin gain
  • Tax line includes a ₹2.35 Cr prior-year credit that boosted reported PAT; underlying (adjusted) PAT growth is still ~274% YoY
  • Basic EPS (not annualised) ₹56.07 vs ₹13.91 a year ago and -₹37.56 in Q4 FY26
  • New Whole-time Director & CEO Amit Mahla (appointed June 19, 2026) signs this result, following a cluster-head resignation on July 4, 2026
  • Standalone only — no consolidated statement filed; single reportable pharmaceutical segment per Ind AS-108